35

1	INTERIM STUDY PROPOSAL 2015-188
2	
3	REQUESTING THE HOUSE COMMITTEE ON PUBLIC HEALTH, WELFARE, AND
4	LABOR STUDY THE SUBSTITUTION OF BIOLOGIC PRODUCTS AND APPROACHES
5	BY OTHER STATES REGARDING THE PROCESS UNDER WHICH PHARMACISTS ARE
6	ALLOWED TO MAKE BIOLOGIC PRODUCT SUBSTITUTION.
7	
8	WHEREAS, the Biologics Price Competition and Innovation Act was enacted
9	on March 23, 2010, to create a new abbreviated process for approval of
10	intended copies of biologic products, including biosimilars, and requires the
11	United States Food and Drug Administration to apply different considerations
12	for approval of generic products; and
13	
14	WHEREAS, a biologic product is a medical product made from human,
15	animal, or microorganism cells that is intended to treat diseases and medical
16	conditions and is much more complex to manufacture than traditional
17	chemically synthesized drugs; and
18	
19	WHEREAS, a biosimilar product is a biologic product that is approved
20	based on a showing that the product is highly similar to a biological product
21	that has been approved by the United States Food and Drug Administration,
22	also known as a reference product, and clinically has no meaningful
23	differences in terms of safety and effectiveness from the reference product;
24	and
25	
26	WHEREAS, the United States Food and Drug Administration has approved
27	three (3) biosimilars, with more currently under review; and
28	
29	WHEREAS, twenty-five (25) states have passed legislation establishing
30	state standards for substitution of biologic products; and
31	
32	WHEREAS, Arkansas law contains standards for the substitution of
33	generic drugs, but does not contain a provision for the substitution of
34	biologic products; and

1	WHEREAS, the General Assembly should pursue all approaches to ensure
2	that the citizens of Arkansas have equal access to all medical products
3	available for use,
4	
5	NOW THEREFORE,
6	BE IT PROPOSED BY THE HOUSE COMMITTEE ON PUBLIC HEALTH, WELFARE, AND LABOR OF
7	THE NINETIETH GENERAL ASSEMBLY OF THE STATE OF ARKANSAS:
8	
9	THAT the House Committee on Public Health, Welfare, and Labor study the
10	substitution of biologic products and approaches by other states regarding
11	the process under which pharmacists are allowed to make biologic product
12	substitution.
13	
14	Respectfully submitted,
15	
16	
17	
18	Representative Stephen Magie
19	District 72
20	
21	
22	
23	
24	
25	
26	
27 28	
29	
30	
31	
32	
33	
34	
35	
36	By: JMB/JMB